Srinivas NR |
Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28589592
|
BenÃtez C et al. |
Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. Authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28589580
|
Schmidt KJ et al. |
Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23121200
|
Yamamoto S et al. |
Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18549460
|
O'Leary JG |
Editorial: tacrolimus-how low can you go? |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28589579
|
Firpi RJ et al. |
Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15113371
|
Herrlinger KR et al. |
Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20175769
|
Solari S et al. |
Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28261844
|
Schwrer H et al. |
Pantoprazole and cyclosporine or tacrolimus. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11284790
|
Trotter JF et al. |
Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963078
|
Nakase H et al. |
Tacrolimus suppresses IL-12/IL23 p40 in Crohn's disease and heals fistulae refractory to anti-TNF-α therapy. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21434949
|
Nakase H et al. |
Tacrolimus: rescue therapy or experimental drug for severe ulcerative colitis? |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21198700
|
Hoshino H et al. |
Effects of FK506 on an experimental model of colitis in rats. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:7544633
|
Lawrance IC and Copeland TS |
Rectal tacrolimus in the treatment of resistant ulcerative proctitis. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18761706
|
Liberal R et al. |
Expert clinical management of autoimmune hepatitis in the real world. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28004405
|
Segal JP et al. |
Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28008631
|
Mehta SJ et al. |
Review article: strategies for the management of chronic unremitting ulcerative colitis. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23718288
|
Yamamoto T et al. |
Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27040167
|
Taylor KM and Sparrow MP |
Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27040166
|
Nakase H et al. |
Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20636704
|